Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$6,396 | -$23,327 | -$3,708 | -$64,384 |
| Dep. & Amort. | $325 | $331 | $334 | $279 |
| Deferred Tax | $0 | $0 | $0 | $8,076 |
| Stock-Based Comp. | $1,625 | $1,803 | $2,103 | $1,720 |
| Change in WC | $3,913 | -$3,923 | -$2,864 | $6,257 |
| Other Non-Cash | -$20,156 | -$4,551 | -$26,963 | $29,487 |
| Operating Cash Flow | -$20,689 | -$29,667 | -$31,098 | -$18,565 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | -$29 | $0 | -$38 |
| Net Acquisitions | -$125 | $0 | $29 | $1,560 |
| Inv. Purchases | $0 | $0 | -$24,669 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | $125 | $25,096 | $0 | $0 |
| Investing Cash Flow | $0 | $25,067 | -$24,640 | $1,522 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | -$3 |
| Stock Issued | -$115 | $115 | $0 | $43,270 |
| Stock Repurch. | $115 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $41 | -$265 | $113 |
| Financing Cash Flow | $0 | $41 | -$265 | $43,380 |
| Forex Effect | $0 | $0 | $0 | $967 |
| Net Chg. in Cash | -$20,689 | -$4,559 | -$56,003 | $27,307 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $81,083 | $83,523 | $139,526 | $112,219 |
| End Cash | $60,394 | $78,964 | $83,523 | $139,526 |
| Free Cash Flow | -$20,689 | -$29,667 | -$31,098 | -$18,603 |